当前位置: 首页 > 期刊 > 《医学信息》 > 2019年第5期
编号:13425630
卵巢癌与非编码RNA研究进展(5)
http://www.100md.com 2019年2月5日 《医学信息》 2019年第5期
     [23]Liang H,Yu T,Han Y,et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J].Mol Cancer,2018,17(1):119.

    [24]Teschendorff AE,Lee SH,Jones A,et al.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer[J].Genome Med,2015(7):108.

    [25]Chen Y,Du H,Bao L,et al.LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214[J].Cancer Biol Med,2018,15(3):238-250.

    [26]Li N,Zhan X,Zhan X.The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes[J].Gynecol Oncol,2018,150(2):343-354.

    [27]Bachmayr-Heyda A,Reiner AT,Auer K,et al.Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer,idiopathic lung fibrosis,and normal human tissues[J].Sci Rep,2015(5):8057.

    [28]Ahmed I,Karedath T,Andrews SS,et al.Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma[J].Oncotarget,2016,7(24):36366-36381.

    [29]Liu N,Zhang J,Zhang LY,et al.CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer[J].Eur Rev Med Pharmacol Sci,2018,22(12):3713-3718.

    收稿日期:2019-1-4;修回日期:2019-1-15

    編辑/肖婷婷, http://www.100md.com(揭嘉慧 张颖)
上一页1 2 3 4 5